Årsrapport 30700228 EY Godkendt Revisionspartnerselskab Værkmestergade 25 Postboks 330, 8100 Aarhus C 2024-01-01 2024-12-31 2023-01-01 2023-12-31 41058439 Teitur Trophics ApS Palle Juul-Jensens Boulevard 82 8200 Aarhus N 2020-01-08 Aarhus EY Godkendt Revisionspartnerselskab 30700228 Værkmestergade 25 8100 Aarhus C 2025-05-23 Simon Mølgaard Jensen Regnskabsklasse B Revisionspåtegning Grundlag for konklusion Konklusion true true 2025-05-23 2025-05-23 CaseWare Working Papers Aarhus Simon Mølgaard Jensen Charles Henry Large Chairman Søren Lemonius Casper Breum Simon Mølgaard Jensen Susanne Stuffers Milla Maria Koistinaho Per Fredrik Lehmann Aarhus Peter U. Faurschou Steffen Michael Bach State Authorised Public Accountant mne34502 State Authorised Public Accountant mne45892 -6189268 -4024278 922693 382425 59725 9026 -7171686 -4415729 210585 1026532 94231 87898 -7055332 -3477095 -737935 -737935 -6317397 -2739160 -6317397 -2739160 171446 149442 13082 0 184528 149442 33858 5474 33858 5474 218386 154916 737935 737935 230020 199158 62483 24657 1030438 961750 6228881 12200024 7259319 13161774 7477705 13316690 20680 20680 5432685 11750082 5453365 11770762 490222 705009 490222 705009 387054 246553 987605 493818 159459 100548 1534118 840919 2024340 1545928 7477705 13316690 5367 -2279393 15313 16899791 -2739160 0 -131156 20680 11750082 -6317397 20680 5432685 916736 380041 5957 2384 922693 382425 6 2 -737935 -737935 160257 0 79113 15698 239370 15698 10815 0 57109 2616 67924 2616 171446 13082 5474 28384 33858 33858 5367 5367 5367 5367 15313 0 0 0 20680 5367 5367 5367 Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Teitur Trophics ApS for the financial year 1 January - 31 December 2024. The annual report is prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2024 and of the results of the Company's operations for the financial year 1 January - 31 December 2024. Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review. We recommend that the annual report be approved at the annual general meeting. To the shareholders of Teitur Trophics ApS We have audited the financial statements of Teitur Trophics ApS for the financial year 1 January - 31 December 2024, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2024 and of the results of the Company's operations for the financial year 1 January - 31 December 2024 in accordance with the Danish Financial Statements Act. We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Independence We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements. As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also: Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management. Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern. Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. Management is responsible for the Management's review. Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review. The company's key activity is to develop novel therapeutics for treating or preventing neurodegenerative diseases. From the Sortilins family of receptors, Teitur has developed cyclic peptides with a unique potential for addressing key pathologies across several neurodegenerative disorders including Huntington’s Disease, Parkinson’s Disease and Frontotemporal Dementia. These diseases impact memory, behaviour, movement and mood of millions of people around the globe and Teitur strive to improve the lives of these patients. The income statement for 2024 shows a loss of EUR 6,317 thousand against a loss of EUR 2,739 thousand last year, and the balance sheet at 31 December 2024 shows equity of EUR 5,453 thousand. The loss for the year is according to expectations. In March 2025 the company completed a tranch 3 capital raise as part of the Series A investment round that was successfully completed in March 2023. In addition to the matters mentioned above, there are no other events materially affecting the Company's financial position have occured subsequent to the financial year-end. Other value adjustments is related to legal costs in connection with capital increases. The annual report of Teitur Trophics ApS for 2024 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities. The accounting policies used in the preparation of the financial statements are consistent with those of last year. Reporting currency The financial statements are presented in euros (EUR), as the Company's most significant transactions are settled in EUR. On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses. Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses. Other operating income comprise items secondary to the principal activities of the Company, including rental income from the temporary lease out of production facilities, compensation, government grants, refund of wages and salaries, gains on the disposal of intangible assets and property, plant and equipment, etc. Compensation and grants are recognised when there is reasonable assurance that the entity will comply with the conditions attaching to them and the grants will be received. Teitur Trophics expenses all research costs. In line with industry practice, internal and sub-contracted development costs are also expensed as they are incurred, due to significant regulatory uncertainties and other uncertainties inherent in the development of new products. This means that they do not qualify for capitalisation as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc. Staff costs comprise wages and salaries, including holiday allowance and pensions, and other social security costs, etc., for the Company's employees. The item comprises depreciation of plant and equipment including leasehold improvements. The basis of depreciation, which is calculated as cost less any residual value, is depreciated on a straight line basis over the expected useful life. The expected useful lives of the assets are as follows: Fixtures and fittings, other plant and equipment 3-5 years Leasehold improvements 5 years Depreciation is based on the residual value of the asset and is reduced by impairment losses, if any. The depreciation period and the residual value are determined at the acquisition date and are reassessed annually. Where the residual value exceeds the carrying amount of the asset, no further depreciation charges are recognised. In the case of changes in the depreciation period or the residual value, the effect on the depreciation charges is recognised prospectively as a change in accounting estimates. Financial income and expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest income and expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc. Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity. Property, plant and equipment Items of plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use. Gains or losses are calculated as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains and losses from the disposal of property, plant and equipment are recognised in the income statement as other operating income or other operating expenses. Deposits, investments Deposits concerns the deposit in connection with lease agreements. Deposits concerns the deposit in connection with lease agreements. The carrying amount of plant and equipment and leasehold improvements is assessed for impairment on an annual basis. Impairment tests are conducted on assets or groups of assets when there is evidence of impairment. The carrying amount of impaired assets is reduced to the higher of the net selling price and the value in use (recoverable amount). The recoverable amount is the higher of the net selling price of an asset and its value in use. The value in use is calculated as the present value of the expected net cash flows from the use of the asset or the group of assets and the expected net cash flows from the disposal of the asset or the group of assets after the end of the useful life. Previously recognised impairment losses are reversed when the reason for recognition no longer exists. The Company has chosen IAS 39 as interpretation for impairment write-down of financial receivables. Receivables are measured at amortised cost. An impairment loss is recognised if there is objective evidence that a receivable is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis. Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable is used as discount rate. Prepayments recognised under "Assets" comprise prepaid expenses regarding subsequent financial reporting years. Cash comprise cash subject only to minor risks of changes in value. Proposed dividends Dividend proposed for the year is recognised as a liability once adopted at the annual general meeting (declaration date). Dividends expected to be distributed for the financial year are presented as a separate item under "Equity". Dividend proposed for the year is recognised as a liability once adopted at the annual general meeting (declaration date). Dividends expected to be distributed for the financial year are presented as a separate item under "Equity". Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account. Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively. Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement. The Company has chosen IAS 39 as interpretation for liabilities. Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan. Financial liabilities also include the capitalised residual lease liability in respect of finance leases. Other liabilities are measured at net realisable value. Note 10 provides more details on security for loans, etc. as regards property, plant and equipment. Of the long-term liabilities, EUR 0 falls due for payment after more than 5 years after the balance sheet date. Rent and lease liabilities include a rent obligation totalling EUR 68 thousand in interminable rent agreements with remaining contract terms of 6 months. The company has tax loss carry-forwards totalling EUR 5,897 thousand. The nominal value thereof is 22%, totalling EUR 1,297 thousand. The tax asset has not been recognised in the balance sheet due to the uncertainty as to application of the tax losses. The Company has not provided any security or other collateral in assets at 31 December 2024. 41058439 2024-01-01 2024-12-31 41058439 2023-01-01 2023-12-31 41058439 2023-12-31 41058439 2024-12-31 41058439 2024-01-01 2024-12-31 1 41058439 2024-01-01 2024-12-31 2 41058439 2024-01-01 2024-12-31 3 41058439 2024-01-01 2024-12-31 4 41058439 2024-01-01 2024-12-31 5 41058439 2024-01-01 2024-12-31 6 41058439 2024-01-01 2024-12-31 7 41058439 2024-01-01 2024-12-31 1 41058439 2024-01-01 2024-12-31 2 41058439 2024-01-01 2024-12-31 1 41058439 2024-12-31 e:ReceivablesFromOwnersAndManagementMember 41058439 2024-01-01 e:FixturesFittingsToolsAndEquipmentMember 41058439 2024-01-01 2024-12-31 e:FixturesFittingsToolsAndEquipmentMember 41058439 2024-12-31 e:FixturesFittingsToolsAndEquipmentMember 41058439 2024-01-01 e:LeaseholdImprovementsMember 41058439 2024-01-01 2024-12-31 e:LeaseholdImprovementsMember 41058439 2024-12-31 e:LeaseholdImprovementsMember 41058439 2023-01-01 e:ContributedCapitalMember 41058439 2023-01-01 2023-12-31 e:ContributedCapitalMember 41058439 2024-01-01 e:ContributedCapitalMember 41058439 2024-12-31 e:ContributedCapitalMember 41058439 2024-01-01 e:RetainedEarningsMember 41058439 2024-01-01 2024-12-31 e:RetainedEarningsMember 41058439 2024-12-31 e:RetainedEarningsMember 41058439 2023-01-01 e:RetainedEarningsMember 41058439 2023-01-01 2023-12-31 e:RetainedEarningsMember 41058439 2023-12-31 e:ContributedCapitalMember 41058439 2002-01-01 e:ContributedCapitalMember 41058439 2022-01-01 2022-12-31 e:ContributedCapitalMember 41058439 2022-12-31 e:ContributedCapitalMember 41058439 2001-01-01 e:ContributedCapitalMember 41058439 2021-01-01 2021-12-31 e:ContributedCapitalMember 41058439 2021-12-31 e:ContributedCapitalMember 41058439 2000-01-01 e:ContributedCapitalMember 41058439 2020-01-01 2020-12-31 e:ContributedCapitalMember 41058439 2020-12-31 e:ContributedCapitalMember 41058439 2024-01-01 e:DepositsLongtermInvestmentsAndReceivablesMember 41058439 2024-01-01 2024-12-31 e:DepositsLongtermInvestmentsAndReceivablesMember 41058439 2024-12-31 e:DepositsLongtermInvestmentsAndReceivablesMember iso4217:EUR xbrli:pure